Zydus Lifesciences: Business Overview & Financial Analysis 

Zydus Lifesciences Limited is a leading Indian multinational pharmaceutical company engaged in discovering, developing, manufacturing, and marketing a wide range of healthcare products. The company operates across finished formulations, active pharmaceutical ingredients (APIs), consumer wellness, animal health, and innovative biopharmaceuticals. With manufacturing facilities in India and global markets, Zydus has a strong presence in Indian branded formulations while also serving North America, Europe, and other international markets with complex generics, biosimilars, and specialty medicines.

Zydus Lifesciences Business Segment Revenue Mix (Q4 FY2025-26)

The company's revenue is well diversified across domestic and international businesses, with North America remaining its largest market.

• North America Formulations – 38.9% of consolidated operational revenue
• India Formulations – 23.1% of consolidated operational revenue
• Consumer Wellness (Zydus Wellness) – 19.3% of consolidated operational revenue
• International Markets Formulations – 10.6% of consolidated operational revenue
• MedTech Business – 4.3% of consolidated operational revenue
• Active Pharmaceutical Ingredients (API) – 1.6% of consolidated operational revenue
• Total Consolidated Operational Revenue – Rs 7,587.00 crore

North America and India continue to be the company's key revenue drivers, while strong growth in consumer wellness and international markets provides additional diversification across its business portfolio.

Zydus Lifesciences Full-Year Consolidated Performance (FY2025-26)

The company reported strong revenue and profit growth during the financial year, supported by improved operating performance.

• Consolidated Revenue from Operations – Rs 27,148.40 crore (+16.8% year-on-year growth)
• Consolidated Operating EBITDA Output – Rs 8,475.10 crore (+20.1% year-on-year expansion)
• Consolidated Adjusted Profit After Tax (PAT) – Rs 5,456.40 crore (+15.0% year-on-year growth)
• Consolidated Operating EBITDA Margin – 31.20% of operational turnover (+80 basis points)
• Recommended Annual Dividend Payout – 100% allocation (Rs 1.00 per share of face value Re 1)
• Approved Equity Share Buyback Size – Rs 1,100.00 crore at Rs 1,150 per share

The company achieved strong financial performance during the year, with higher sales and improved operating margins. Better product mix and operating leverage supported profitability despite continued investment in research and development.

Zydus Lifesciences Latest Quarterly Consolidated Performance Metrics (Q4 FY2025-26)

The March quarter reflected healthy revenue growth and improved operating margins.

• Consolidated Quarterly Operational Revenue – Rs 7,587.00 crore (+16.2% year-on-year growth)
• Consolidated Quarterly Operating EBITDA – Rs 2,554.40 crore (+20.2% year-on-year expansion)
• Consolidated Quarterly Reported Net Profit (PAT) – Rs 1,272.50 crore (+8.7% year-on-year growth)
• Consolidated Quarterly Adjusted Net Profit – Rs 1,592.90 crore (+14.6% year-on-year surge)
• Core Quarterly Operating EBITDA Margin – 33.70% of operational turnover (+110 basis points)
• One-Time Exceptional Litigation Adjustment – Rs 397.50 crore Mirabegron settlement expense

Quarterly profitability remained strong despite the one-time litigation expense related to the Mirabegron settlement. Higher domestic sales and improved operating efficiency helped expand EBITDA margins.

Zydus Lifesciences India Formulations & Consumer Business Metrics (Q4 FY2025-26)

The domestic business continued to deliver strong growth across branded formulations and consumer wellness.

• India Formulations Sourced Revenue – Rs 1,752.80 crore (+14.0% year-on-year growth)
• Consumer Wellness Sourced Revenue – Rs 1,463.30 crore (+61.1% year-on-year growth)
• India Branded Formulations Growth Driver – Cardiology, respiratory, and dermatology portfolios
• Landmark Biosimilar Launch (Oncology) – World's first biosimilar of Nivolumab launched under Tishtha™
• Indigenous Biosimilar Launch (Ophthalmology) – Biosimilar Aflibercept launched under Anyra™
• Obesity & Diabetes Portfolio Expansion – Semaglutide injection launched under Semaglyn™, Mashema™, and Alterme™

The India business continued to outperform the broader pharmaceutical market, supported by strong growth in chronic therapies. New biosimilar launches and the expansion of its obesity and diabetes portfolio further strengthened the company's domestic presence.

Zydus Lifesciences North America & International Formulations (Q4 FY2025-26)

International operations remained an important growth driver during the quarter.

• North America Formulations Revenue – Rs 2,952.30 crore (-5.7% YoY / +5.3% QoQ)
• Constant Currency US Dollar Revenue – USD 323 million generated in Q4 FY2025-26
• International Markets Formulations Revenue – Rs 804.10 crore (+45.0% year-on-year growth)
• Quarterly US Generic Product Launches – 6 new products launched in North America
• ANDA Filings & Regulatory Approvals – 3 new ANDA filings submitted; 9 ANDA approvals received
• Specialty Rare Disease US Launch – Zycubo® launched for Menkes disease treatment

International markets recorded strong growth during the quarter, while North America delivered sequential improvement supported by new product launches and continued expansion in specialty medicines.

Zydus Lifesciences Research, Pipeline & Innovation KPIs (FY2025-26)

The company continued investing in research and innovation to strengthen its long-term product pipeline.

• Annual Research & Development (R&D) Spend – Rs 2,273.20 crore (8.4% of total operational revenue)
• Quarterly R&D Allocation Investment – Rs 698.20 crore (9.2% of quarterly revenue)
• International Regulatory Milestone – Desidustat received official regulatory approval in China for renal anemia
• USFDA Orphan Drug Designation – Secured USFDA Orphan Drug Designation for sickle cell disease
• Advanced Clinical Trial Progress – DCGI approval granted for Phase III trials of anti-malarial candidate Zintrodiazine

The company continues to invest heavily in research, with a focus on biosimilars, specialty medicines, and innovative therapies. Recent regulatory approvals further strengthen its global innovation pipeline.

Zydus Lifesciences Balance Sheet Quality & Solvency Profile (As of March 31, 2026)

The company maintains a healthy balance sheet supported by low leverage and strong cash generation.

• Consolidated Net Debt to Equity Ratio – 0.16x maintained at fiscal year-end
• Consolidated Net Debt to EBITDA Ratio – 0.50x leverage allocation
• Full-Year Organic Capital Expenditure Deployed – Rs 1,714.50 crore spent on asset toolings
• Quarterly Organic Capital Expenditure Deployed – Rs 357.70 crore in Q4 FY2025-26

Low debt levels and healthy cash flows provide the company with financial flexibility to invest in research, expand manufacturing capacity, and pursue strategic acquisitions.

Zydus Lifesciences M&A Strategy & Corporate Actions (FY2025-26)

The company continued expanding its global specialty business while returning capital to shareholders.

• Strategic Overseas Acquisition Target – Assertio Holdings, Inc. (US-based specialty pharma)
• Agreed Total Cash Transaction Consideration – USD 166 million (~Rs 1,380 crore equivalent)
• Strategic M&A Objective – Expand US specialty neurology and pain management footprint
• Capital Return Buyback Size – 95.65 lakh equity shares (~1.0% of total paid-up capital)

The acquisition of Assertio Holdings strengthens the company's specialty pharmaceutical business in the US market. Alongside this, the share buyback reflects management's commitment to enhancing shareholder returns.

Zydus Lifesciences Management Commentary & Strategic Guidance (Q4 FY2025-26)

Management remains focused on sustaining growth through innovation, international expansion, and disciplined capital allocation.

• FY2026-27 Revenue Outlook Guidance – Management targets high teens overall revenue growth in FY2026-27, supported by domestic formulations and international markets.
• Consolidated Margin Retention Targets – Leadership expects long-term operating EBITDA margins to stabilize around the 24.0% to 26.0% target corridor.
• North American Segment Growth Expectation – Management anticipates single-digit growth in North America due to base generic price erosion and lack of large generic launches.
• Near-Term M&A Integration Priorities – Sourcing protocols will focus on swift integration of Assertio Holdings to realize commercial distribution synergies.
• Quality & Compliance Execution Directives – The executive team remains focused on maintaining uniform global quality standards across all manufacturing facilities.
• Capital Deployment Strategy Focus – Management confirms that strong internal cash flows ensure full flexibility to fund greenfield R&D and strategic inorganic ventures.

The company plans to strengthen its biosimilar and specialty medicine portfolio, integrate recent acquisitions, and continue investing in innovation while maintaining strong profitability.

Citations

[1.1.1] NDTV Profit Video & Univest Market Intelligence: Zydus Lifesciences Q4 FY26 Results, Revenue Growth, and Share Buyback Analysis (May 19, 2026).
[1.2.1] Indian Pharma Post: Zydus Lifesciences Reports FY26 Revenue of Rs 27,148 Crore, Q4 EBITDA Margins, and Management Commentary (May 20, 2026).
[1.2.2] Innovacia Insights Corporate Desk: Zydus Lifesciences Reports Strong FY26 Performance, Buyback Announcement, and Assertio Acquisition Details (May 20, 2026).
[1.3.2] Business Standard Companies Desk: Zydus Lifesciences Q4 FY26 Results, India Formulations, Biosimilar Launches, and Segment Metrics (May 19, 2026).
[1.3.3] Ventura Securities Research Pulse: Zydus Lifesciences Hits 52-Week High After Strong Q4 FY26 Results, Financial Highlights, and R&D Updates (May 20, 2026).
[1.3.4] SAHI Research & Analytics Hub: Zydus Lifesciences Posts Profit Growth, FY27 Revenue Guidance, and Buyback Structure Analysis (May 2026).

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters

Disclaimer
The information presented above on Zydus Lifesciences has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Zydus Lifesciences page before making any investment decision.